Buy SS-31 (Elamipretide) Peptide: Benefits, Dosage & Mitochondrial Research (2026)
Direct answer: SS-31 is another name used for elamipretide, a four-amino-acid mitochondrial cardiolipin-binding peptide. U.S. researchers can compare the current SS-31 research listing, its lot-matched analytical record, and the now-separate FDA-approved Forzinity product record. The approved product and a catalog research material contain related active-molecule language, but they are not interchangeable products.
Fact-checked by NEXTWAVE PEPTIDES Editorial Team

Listed strengths: 10, 20, and 50 mg per vial · Package: 10 vials per box · Observed starting price: $139 on November 10, 2026.
Review the current SS-31 (Elamipretide) peptide record and matching batch documentation before selecting laboratory material.
SS-31, elamipretide, and Forzinity are related—but not identical records
SS-31 is the research name commonly associated with elamipretide. Forzinity is a finished prescription product whose label specifies elamipretide, formulation, concentration, route, indication, storage, and administration. A research vial instead needs its own stated molecular form, expected mass, content, purity method, lot, and report date. The SS-31 cardiolipin evidence review explains how membrane-binding claims should be attached to the material and assay actually tested.
The 2025 FDA label identifies Forzinity as a mitochondrial cardiolipin binder approved under accelerated approval to improve muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kg. That indication is narrow and product-specific.
Benefits and dosage: which record supplies the answer?
| Question | Best evidence record | What it establishes | What stays separate |
|---|---|---|---|
| Molecular target | Mechanistic membrane studies | Interaction with cardiolipin-rich mitochondrial membranes | Clinical benefit and commercial lot identity |
| Approved dosage | Current Forzinity label | 40 mg subcutaneously once daily for labeled patients weighing at least 30 kg, with labeled renal guidance | Research protocols and supplier vial strengths |
| Clinical outcomes | Barth syndrome trials and FDA review | Defined endpoints in a very small rare-disease population | Other mitochondrial conditions |
| Research purchase | Product page plus lot COA | Listed amount, package, analytical identity, and lot traceability | FDA-approved finished-product status |
A phase 2/3 crossover trial enrolled 12 people with Barth syndrome. Its randomized crossover phase did not meet the two primary endpoints; an open-label extension reported changes in walking, symptoms, and muscle strength over longer follow-up. The primary trial report is useful because it preserves the population, dose, endpoints, crossover design, and extension separately.
FDA's Drug Trials Snapshot confirms that the pivotal program was exceptionally small and that accelerated approval rests on an intermediate endpoint with confirmatory work required. This is a meaningful human record, but it should not be rewritten as proof for every mitochondrial condition or every SS-31 research lot.
How to compare SS-31 suppliers
Start with molecular identity. The listing should state SS-31/elamipretide clearly, identify the salt or counterion when relevant, and provide the expected molecular mass. Next compare labeled amount with the analytical content record. Purity by HPLC helps characterize related species, while an orthogonal identity method such as mass spectrometry addresses a different question. A single purity percentage cannot replace identity, content, or lot matching.
Then compare package economics on the same basis. A 10-vial box at 10 mg per vial contains a different total labeled amount from a 20 mg or 50 mg option. Price per box and price per labeled milligram answer different purchasing questions. Current options are organized in the Research Compounds collection, and available lot reports can be checked in the COA library.
The MOTS-c vs SS-31 comparison is also useful when a project involves mitochondrial signaling: MOTS-c and SS-31 differ in sequence, origin, target framing, and evidence base even though both appear in mitochondrial-research searches.
SS-31 versus MOTS-c: choose by research question
SS-31 and MOTS-c both appear in mitochondrial-peptide searches, but they organize experiments differently. SS-31 is a synthetic tetrapeptide commonly studied through cardiolipin and inner-membrane models. MOTS-c is a mitochondrial-derived 16-amino-acid peptide studied in metabolic and stress-signaling models.
That difference changes the starting assay. A membrane-focused SS-31 project may prioritize cardiolipin composition, membrane potential, respiratory-chain behavior, or oxidative-stress readouts. A MOTS-c project may emphasize AMPK-related signaling, gene expression, substrate use, or stress adaptation.
Researchers comparing both can review the separate MOTS-c research peptide record. Each material needs its own sequence, expected mass, form, lot, and evidence table; sharing a mitochondrial theme does not make the compounds interchangeable.
Protocol planning before purchasing SS-31
- Define the model: record species, cell line, tissue, disease model, and mitochondrial endpoint.
- Define the molecule: state SS-31/elamipretide form, expected mass, and reference standard.
- Match concentration units: distinguish vial strength from final assay concentration and total experiment demand.
- Plan controls: include vehicle, time-matched control, and assay-specific positive or negative controls when appropriate.
- Preserve the lot trail: save the product page, COA, receipt date, storage log, and aliquot history.
This planning step makes price comparisons more accurate. A lower-priced box can become more expensive if the available strength creates excess unused material, while a higher-strength option can be efficient only when the study design and stability plan support it.
Document the decision before purchase so later reviewers can reconstruct why a particular strength, lot, supplier record, and control design were selected.
Original analysis: use a three-layer verification model
A reliable SS-31 review uses three linked layers. The molecule layer defines sequence, form, expected mass, and target model. The clinical layer defines the exact finished product, population, dose, endpoint, and approval status. The lot layer defines what was received from a supplier. Keeping the layers separate makes the evidence more useful, not less: researchers can see precisely which conclusion belongs to which record.
For procurement, create one row per offered strength with box price, number of vials, total labeled milligrams, lot number, identity method, purity method, report date, and warehouse statement. This exposes apparent discounts that actually reflect a smaller total amount or incomplete documentation.
Research limitations
Human evidence is concentrated in a rare Barth syndrome population and a small development program. Accelerated approval is not a general mitochondrial-health claim. Research-vial pricing and stock can change, and a supplier COA describes an analytical lot rather than clinical equivalence to Forzinity.
Frequently asked questions
Is SS-31 the same molecule as elamipretide?
SS-31 is a widely used research name for elamipretide, but researchers should still verify form, sequence, expected mass, and lot documentation.
What is the FDA-approved elamipretide dosage?
The current Forzinity label gives 40 mg once daily for labeled patients weighing at least 30 kg and includes product-specific instructions. That is not a laboratory protocol.
What should an SS-31 COA include?
Look for lot matching, identity method, expected and observed mass, content basis, purity method, report date, and traceable sample identification.
How should prices be compared?
Compare box price, vial count, strength per vial, total labeled amount, documentation, and fulfillment terms together.